Several preclinical and clinical trials have investigated mGLUR antagonists for the treatment of social deficits in ASD [78, 79] and ASD associated with FXS [80, 81] and PKCG inhibitors could represent a novel treatment strategy to ameliorate cognitive and social deficits. Here, PRKCG is linked to fragile X syndrome.